Suven Life Sciences reveals breakthrough with Ropanicant in depression treatment

Pallavi Madhiraju- September 19, 2024 0

Suven Life Sciences Limited has made a significant advancement in the fight against depression, announcing positive results from a Phase-2a proof-of-concept study involving Ropanicant (SUVN-911). ... Read More

Johnson & Johnson seeks FDA approval for SPRAVATO in treatment-resistant depression

Pallavi Madhiraju- July 22, 2024 0

Johnson & Johnson (NYSE: JNJ) is seeking U.S. Food and Drug Administration (FDA) approval for SPRAVATO (esketamine) as a standalone treatment for adults with treatment-resistant ... Read More

Sage Therapeutics, Biogen get ZURZUVAE FDA approval for postpartum depression treatment

Pallavi Madhiraju- August 5, 2023 0

Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) announced the U.S. Food and Drug Administration (FDA) approved ZURZUVAE (zuranolone) 50 mg for adults ... Read More

Granules India gets Venlafaxine ER Capsules FDA approval

Pallavi Madhiraju- May 19, 2023 0

Granules India has secured approval for its abbreviated new drug application (ANDA) for Venlafaxine Hydrochloride Extended-Release (ER) Capsules USP, 37.5 mg, 75 mg, and 150 ... Read More

Digital medicine firm Akili Interactive to merge with Social Capital Suvretta

Pallavi Madhiraju- January 29, 2022 0

Akili Interactive, a US-based digital medicine company, has agreed to merge with Social Capital Suvretta Holdings Corp. I (SCS), a special purpose acquisition company (SPAC), ... Read More

Sage Therapeutics secures $3.1bn worth licensing deal for zuranolone and SAGE-217 with Biogen

pharmanewsdaily- November 29, 2020 0

Sage Therapeutics has secured a global collaboration and licensing deal worth up to $3.1 billion with Biogen for two of its drug candidates intended for ... Read More

Tenzing to acquire clinical-stage pharma company Reviva Pharmaceuticals

pharmanewsdaily- July 21, 2020 0

Tenzing Acquisition has agreed to acquire Reviva Pharmaceuticals, a California-based clinical-stage pharma company, focused on developing therapies for addressing unmet medical needs in the areas ... Read More

Usona Institute gets FDA breakthrough status for psilocybin in MDD

pharmanewsdaily- November 23, 2019 0

Wisconsin-based Usona Institute has been granted breakthrough therapy designation for psilocybin from the US Food and Drug Administration (FDA) for the treatment of major depressive ... Read More